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Abstract
Optical coherence tomography (OCT) is a new method potentially
applicable for the analysis of neurodegeneration in multiple sclero-
sis (MS) by capturing thinning of the retinal nerve fibre layer (RNFL).
Metaanalyses of time domain OCT (TDOCT) data demonstrates RNFL
thinning of 20 µm (95%CI 18-23, n=2063, p¡0.00001) following MS
optic neuritis (MSON) and µm (95%CI 6-9, n=3154, p¡0.00001) in
MS without MSON. The estimated RNFL thinning in patients with MS
is above what is expected from normal ageing. The likely cause being
retrograde trans-synaptic degeneration and progressive loss of reti-
nal ganglion cells. The RNFL correlated with visual and neurological
functioning as well as with paraclinical data. Promising developments
in order to better understand the structurefunction relationship in MS
pathophysiology include spectral/Fourierdomain OCT (SD/FDOCT)
technology, polarisation sensitive OCT, fluorescence labelling, struc-
tural assessment of action potential propagation and segmentation
algorithms allowing for quantitative assessment of different retinal lay-
ers.
Word count: abstract 145, main text 5340.
Keywords optical coherence tomography, retinal nerve fibre layer, ax-
onal loss, neurodegeneration, multiple sclerosis
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1 Introduction
Optical coherence tomography (OCT) is a non–invasive technique1 which
allows for an “optical biopsy” of accessible tissues such as the retina (Fig-
ure 1). Over the past decade OCT matured into an interesting, highly sen-
sitive tool for imaging of neurodegeneration in multiple sclerosis (MS) re-
search.2,3 Because the retina is the only place where a tissue layer made
up of axons can be imaged directly, quantification of the retinal nerve fibre
layer (RNFL) has the potential to open a diagnostic window on monitoring
neurodegeneration.
Here we present a systematic review of studies investigating OCT in
patients with MS. Special care is taken to distinguish axonal damage caused
by MS clinically evident optic neuritis (MSON) from more subtle retinal ax-
onal damage in non–affected MS eyes. We will review the anatomical func-
tional correlations, first focusing on the visual system and second, focusing
on more global measures of disability in MS. The relationship of OCT data
to established electrophysiological techniques and imaging modalities will
also be discussed. Finally, we will provide a glimpse into future research
areas of advanced OCT imaging that might influence assessment of ax-
onal damage relevant to assessing a patient’s MS activity and response to
therapy.
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2 Methods
Search strategy and selection criteria The review of the Dutch, En-
glish, French, German, Italian and Spanish literature was conducted on
all studies using OCT in MS patients between the first description of the
method by Huang1 and May 2010, including manuscripts published ahead
of print. We searched pubmed, EMBASE, medline, web of science and the
Cochrane Register of Diagnostic Test Accuracy Studies using the search
terms: multiple sclerosis, MS, optic neuritis, ON, optical coherence tomog-
raphy, OCT, retinal nerve fibre layer, RNFL. From 99 studies identified, 62
were excluded because they were reviews, did not use the Stratus OCT,
were single case reports, communications in response to an article, dupli-
cation of data already published on this cohort or data presentation were
not detailed enough to allow inclusion into a meta–analysis. Studies that
did not include a control cohort were only included if they compared the
ON affected and not affected eye in MS patients. From the 37 included
studies 35 presented data suitable for meta–analysis of RNFL thickness
between groups.4–38
Statistical analysis The data analysis used the Cochrane Collabora-
tion’s Review Manager software package (RevMan5) following the guid-
ance of the Diagnostic Test Accuracy (DTA) Working Group. The published
RNFL thickness data was entered as a continuous variable. We used in-
verse variance, with random effects in the model. For effect measure we
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chose the mean difference which allows to compare the RNFL thickness
in µm between the groups of interest. Three group comparisons for the
RNFL thickness were performed: (a) MSON eyes with controls eyes, (b)
MS eyes without history of MSON and control eyes, (c) in the same MS
patient the MSON eye with the non–affected eye. Regression analyses
were performed using SAS software (version 9.1.3). A p-value of ≤ 0.05
was regarded as significant.
3 OCT in Multiple Sclerosis
Axonal loss in the retina With the invention of the ophthalmoscope (von
Helmholtz, 1851), in vivo detection of atrophy of the optic disc became
technically possible. For example, Gowers described sectoral RNFL loss
in a woman suffering from syphilis. In his case the remaining nerve fibres
were more visible because of swelling (plate II, figure 2 in reference39). A
later case of sectoral RNFL loss in which sequential in vivo images permit-
ted to evoke the concept of ascending axonal degeneration (now known
as Wallerian degeneration) was facilitated by the rare presence of myeli-
nated fibres in the retina.40 Bachmann describes a 28 year old man in
whom sudden loss of vision in the right eye on the 22nd of January 1920
was due to a central retinal artery occlusion. Within two months after the
retinal vascular event, the RNFL loss became visible as degeneration of
bundles of myelinated retinal axons (Figure 2 A), progressing over the fol-
lowing two months (Figure 2 B) and leading to complete optic atrophy and
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loss of myelinated axons observed on fundus exam within one year (Figure
2 C).40 There is good post–mortem evidence for RNFL thinning in MS.41
RNFL in MSON In multiple sclerosis, following optic neuritis (MSON), the
degree of RNFL loss in thickness is in the range of 5–40 µm, averaging at
10–20 µm.6 The finding was significant for all studies using time domain
OCT (TD–OCT) technology based on the Stratus OCT (Zeiss, software
version 3.0 & 4.0) that we identified in a systematic literature review. The
summary data of 14 studies on MS patients with MSON,4,10,11,16,18,19,21–27,30,31
containing a total of 2063 eyes tested with OCT are presented in Figure 3.
From two of these studies the data published were not in a format allowing
inclusion into the meta–analysis and more detailed information could not
be obtained from the authors.24,28 The results of the meta–analysis on the
remaining 12 studies4,10,11,16,18,21,22,25–27,30,31 are highly significant with an
estimated average RNFL loss of -20.38 µm [-22.86, -17.91].
An important limitation of these studies is that optic nerve damage, in-
dependent of whether it occurs in the context of MS (MSON) or due to
other causes (for a thorough clinical review see reference42) will cause
some degree of RNFL loss. In an elegantly conducted small case series,
Choi et al. present detailed OCT data on patients with several different
kinds of optic neuropathy.43 Any form of optic nerve damage was associ-
ated with marked thinning of the RNFL. Therefore the question arises as
to whether the presence of MSON could have introduced a bias towards
more damage and RNFL thinning into the studies presented in Figure 3.
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In the absence of MSON, retrograde trans-synaptic retinal ganglion cell
degeneration due to MS lesions within the posterior optic pathways could
be a cause for RNFL loss. The existence of retrograde trans–synaptic
retinal ganglion cell degeneration has been proven in patients with cere-
brovascular accidents affecting the posterior visual pathways and cortex.44,45
In a combined MRI/OCT study Reich et al. showed that damage to
the optic radiations in MS was associated with a reduced averaged global
RNFL.46 There is a need to investigate whether the recently recognised ef-
fect of post geniculate lesions44,45 on the RNFL can be distinguished from
RNFL loss caused by subclinical damage to the anterior visual pathways
in MS as suggested by VEP studies.47–51
RNFL in MS without MSON We identified 16 studies which compared
the RNFL thickness in patients with MS without evidence for ON to a con-
trol population,4,10,11,14–16,19,21,22,25–28,30,31 of which 15 provided data in a
format allowing inclusion into the meta–analysis.4,10,11,14,16,21,22,25–28,30,31
The summary data on the 3154 eyes investigated is presented in Figure
4. The estimated RNFL loss (-7.08 µm) was less compared to MSON
(-22.86 µm), but the 95% CI were markedly smaller [-8.65, -5.52]. This
highlights the importance for carefully looking for evidence of MSON in or-
der to minimise the risk that detection of the more subtle RNFL loss due
to presumed retrograde trans–synaptic retinal ganglion cell degeneration
may be masked by the pronounced loss caused by damage to the anterior
visual pathways.
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RNFL in MS comparing MSON eyes with the contralateral eye To ad-
dress this question 27 studies compared the affected (MSON) eye to the
clinically non–affected eye in MS patients.4–6,8–11,13,16,17,21–25,27,29–38 The
meta–analysis on the 4199 eyes investigated clearly illustrates the signifi-
cant effect that presence of MSON has on RNFL (Figure 5). The estimate
RNFL loss (-13.84 µm) is larger than what was seen for the comparison
of MS without MSON to controls (-7.08 µm), but the confidence intervals
were overlapping. An important prognostic finding of these studies is that
after reaching a threshold of thinning to about 75 µm of RNFL thickness,
the chances for recovery of visual function seem to be less.6
Conclusion Taken together the published data4–27,29–38 suggests a rela-
tionship between RNFL thinning and MS pathology as illustrated in Figure
6. The retinal axons project through the optic nerve into the lateral genic-
ulate nucleus (LGN). About 90% of retinal axons synapse in the LGN and
travel with the optic radiations to the occipital cortex. The remaining 10%
project into the pretectal region of the midbrain. Severe thinning of the
RNFL layers follows MSON directly (Figure 6 B). These acute changes in
MSON patients can be distinguished from more chronic changes caused
by MS pathology of the optic pathways. An MS lesion affecting fibres in
the optic radiation will cause Wallerian degeneration of some axons which
reaches the LGN only after some time. Due to trans–synaptic degenera-
tion retrograde axonal degeneration will eventually cause some degree of
RNFL thinning (Figure 6 C). It is also likely that progressive loss of retinal
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ganglion cells (RGC) occurs as a result of chronic changes in the optic
nerves/anterior visual pathways themselves (Figure 6 D). To test this hy-
pothesis we reviewed the literature for the time course of RNFL loss in MS
patients with and without MSON.
4 Time course of RNFL loss in MS
As a rule of thumb, RNFL loss becomes readily detectable to OCT about 3
months after an acute optic neuritis (ON). Earlier reduction in RNFL thick-
ness from axonal atrophy is clinically difficult to distinguish from a reduc-
tion due to resolution of axonal swelling, which is common in acute optic
neuritis. Costello et al. presented longitudinal data on the RNFL thickness
during the first 12 months following ON (see Figure 7). This data shows
ongoing axonal loss in the affected eye for at least 12 months, but most
thinning occurs by 6 months after injury.
An inverse correlation between disease duration and the averaged over-
all RNFL thickness was found by some R=-0.262, p=0.011,19 R=-0.6, p=0.02,25
p=0.03 (R–value not published),10 but not by others.15,16 Examining non–
MSON eyes Henderson et al. found that the RNFL decreased by 0.12mum
per year of disease (95%CI: -0.50, 0.25), but this failed statistical signifi-
cance (p=0.513).15 Investigating MSON eyes, Klistoner et al. did not find a
correlation between RNFL thickness and disease duration (p=0.9, R–value
not published).16 The divergent results10,15,16,19,25 may in part be explained
by the variation in average disease duration and a bias in the population of
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MS patients studied. A meta–regression analysis of the studies’ raw data
may help to shed light on the presumed association between RNFL loss
and disease duration, but the most accurate information will come from
longitudinal studies, where the RNFL thickness in individual patients can
be studied over time. Talman et al. published longitudinal data from 593
eyes which were assessed at baseline and≥ 6 months later.38 Their statis-
tical analysis was corrected for patients age and adjusted for within-patient
and inter eye correlations. For MSON eyes the percentage decrease of
RNFL thickness compared to baseline was 0.4% (0.4µm; 95%CI: 1.16, -
0.35) for eyes with a 0.5–1 year follow–up period; 1.7% (1.6µm; 95% CI,
2.47, 0.70) for >1 to 2 years; 3.2% (2.9µm; 95% CI, 4.02, 1.86) for >2 to 3
years; and 6.7% (6.1µm; 95% CI, 7.73, 4.41) for >3 years of follow-up. In
comparison the average RNFL thinning for disease–free control eyes was
0.5% (0.49µm; 95% CI, 1.36, -0.39) over a 3-year period.38 Their pooled
analysis (MSON eyes and non-MSON eyes) showed that each year of
follow–up was associated with an , on averaged 2 µm increase of RNFL
thinning (p<0.001, generalised estimating equation models).38
Conclusion One needs to be very careful drawing conclusions on the
time course of RNFL loss in an individual eye from cross–sectional data.
The data suggest that in MS without MSON the estimated yearly thinning
of the overall RNFL (≈ 2 µm38) is probably below the detection limit of
TD-OCT systems. Theoretically, the newer Spectral or Fourier domain
OCT (SD/FD-OCT) systems should be able to enable resolution at this
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level,52–55 but practically a resolution of 4–6 µ was found for the Heidelberg
spectralis and Cirrus HD-OCT.56 There was (yet) no quantifiable RNFL
loss in patients with a recent onset (average of 4.3 months) clinically iso-
lated syndrome (CIS) if compared to healthy controls.57 The current du-
ration of phase II trials in MS is frequently around 4–6 months and it is
not likely that OCT will provide a reliable outcome over this time–scale.
From the above data one would expect that MS patients without MSON
will require follow–up for at least two years.
The longitudinal monitoring of the RNFL is technically challenging. Two
methods have been validated clinically: topographic change analysis (TCA)
and statistical image mapping (SIM).58–61 There is no consensus yet on
how to collect and analyse longitudinally collected OCT data in MS.
5 OCT and disability in MS
There are well characterised limitations to the clinical disability scales cur-
rently employed in MS research,62 not least of which is that they fail to fully
capture the range of disability seen in the disease, especially if they are
not in the domain of patient mobility and motor function. Useful surrogate
markers are challenging to validate.
The driving force of disability in MS, axonal loss, appears to be as-
sociated with changes in the RNFL which are statistically related to the
changes observed in clinical disability progression.4–27 (Figures 3–5). Be-
cause the RNFL is anatomically related to visual function, studies analysing
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this relationship are reviewed first. There are good arguments that RNFL
loss also reflects neurodegeneration on a more global level2,3 stimulating
additional review of the robustness of the relationship between RNFL loss
and global clinical disability scales. In reviewing this literature, it is im-
portant to keep in perspective that almost all of the studies to date are
performed on group analysis.
5.1 Visual function
Visual acuity Monocular visual acuity (VA) is commonly assessed using
standard eye charts. The method was introduced by the Dutch ophthalmol-
ogist Hermann Snellen in 1862.63 The current convention is to document
the Snellen equivalent (20/10–20/200). There are methodological limita-
tions of the Snellen charts and of the many published improvements this
review will consider Early Treatment Diabetic Retinopathy Study (ETDRS)
charts and low contrast acuity (Sloan charts) in a separate paragraph.
Loss of RNFL was associated with reduced Snellen VA in most5,6,18,19,21,27,64–66
but not all13 studies. A linear correlation between loss of Snellen VA and
the RNFL was observed in three studies.18,64,65 The strongest correlations
(R>0.6) were found in studies including MSON patients.18,64,65 Compara-
ble results were found for use of standard Japanese decimal VA.35
Early Treatment Diabetic Retinopathy Study (ETDRS) charts The ET-
DRS charts have a number of advantages over the Snellen VA, one being
that the use of logarithmic scaling (logMAR), permits adjustment of the VA
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score to the viewing distance.67 Essentially a logMAR score provides inter-
val data which facilitate statistical analyses and is therefore recommended
for use in clinical trials.68 Trip et al. found a linear correlation between
the interocular difference in the logMAR score and the RNFL thickness.26
Henderson et al confirmed the correlation of the RNFL with the logMAR
score (R=-0.54, p<0.001).15 Costello et al. also observed such a correla-
tion six months after MSON.7 In a mixed cohort of untreated MS patients
with or without MSON, Spain et al. reported a linear correlation (R=-0.53,
p<0.001)29 which is consistent with the results of Siepman et al. (R=-0.56,
p<0.01).37
Low contrast letter acuity Balcer et al. first suggested integrating (binoc-
ular) low contrast letter acuity (Sloane charts) into a modified Multiple Scle-
rosis Functional Composite (MSFC) based on her observation that MS pa-
tients could be significantly (p<0.0001) better distinguished from controls
at a 1.25% contrast level compared to ETDRS charts.69 The authors also
found Pelli–Robson charts to be of use, albeit at a lower level of signifi-
cance (p=0.003). The results were confirmed in later studies.38,70
Fisher et al. found a one–line change of 1.25% low–contrast letter acu-
ity for every 4µm of RNFL lost.10 A strong correlation (R=0.63, p=0.02)
between low contrast acuity and RNFL thickness in affected MSON eyes
was described in two other studies,11,27 a finding confirmed independently
in patients with PPMS (R=-0.46, p=0.026).15 A moderate correlation be-
tween the RNFL and 2.5% charts (R=0.39, p<0.001) and 1.25% charts
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(R=0.31, p<0.001) was found in one study.21 In line with these studies are
the results of Spani et al. using 1.25% Sloan charts (R=-0.34, p=0.02).29
Currently, there are no longitudinal studies showing good correlation be-
tween RNFL and VA over time.
Visual fields (VF) Multiple sclerosis can produce any type of VF defect.
The most common VF defects in acute MSON are dense but transient sco-
toma which are central, altitudinal or centro–caecal.42,71,72 Achromatic
static perimetry is typically used for assessment of VF loss. The sensitiv-
ity of this technique is limited when supra–threshold screening strategies
are used and improves with threshold estimation strategies.73,74 The like-
lihood to underestimate VF loss depends on the number of stimuli tested,
stimulus size, the threshold loss and the control of eye–movements.
Costello et al. used the central 30-2 full threshold strategy (Humphrey)6
which is sensitive and gives a good overview. The authors found a rela-
tionship between the RNFL thickness and VF 3-6 months after ON. Below
a threshold of 75 µm RNFL loss, a linear correlation was found with the VF
mean deviation (MD) in decibels (dB) ∗. Importantly, there was no recovery
of visual function in these patients. A RNFL thickness of less then 75 µm is
considered to be a poor prognostic sign.7,22,23 The results of Costello et al.
are consistent with those by Trip et al who described a linear correlation
between the interocular difference in the RNFL thickness and VF MD us-
∗Authors note: the VF MD is one of four global indices provided by the Humphrey
perimeter. The MD gives the average of differences from normal expected value for the
patients age. The MD is useful for detecting diffuse VF loss as it is the case in MSON.
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ing the same protocol.26 A weak correlation between the averaged RNFL
thickness and the MD VF was also confirmed by others.15,19,37,64 Noval et
al. described an association between RNFL loss and VF 1.5 and 3 months
after MSON, but not any more after 6 months.64 The authors conclude that
OCT may detect RNFL damage at a level which is below the sensitivity of
automated static perimetry which is consistent with other studies.20
Cheng et al. used a VF severity score and found a better correlation
for the RNFL with the overall VF loss compared to quadrant VF loss.5
The authors suggest this may be due to (a) diffuse instead of localised
RNFL defects in MS, (b) a poor structure–to–function map, as reasons for
the limited topographic correlations,5 and suboptimal image registration on
TD–OCT in some patients offers an alternative explanation. Trip et al. also
failed to show an association between a temporal VF defect and loss of
RNFL thickness in the corresponding RNFL sector.26 They point out that
the Humphrey 30-2 program tests far less points in the nasal and tempo-
ral sectors than in the superior and inferior sectors, potentially leading to
greater noise due to reduced sampling.
5.2 Global clinical scores
EDSS Twelve studies examined the relationship between loss of RNFL
and progression on the EDSS.4,9,10,12,13,18,24,25,28,37,65,75 An inverse corre-
lation between the RNFL and the EDSS was observed in 6 studies (R=-
0.348,24 R=-0.7,25 R=-0.399,75 R=-0.30,37 R=-0.42 MS patients without
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MSON4 and partial R=-0.35 using the minimal RNFL thickness12). This
data is consistent with analyses from two further studies describing a sig-
nificant reduction of the RNFL with increasing EDSS percentiles.10,13 Four
studies did not find a relationship between the RNFL and the EDSS.18,28,36,65
One of these studies included NMO and MS patients,18 another presented
detailed data on both variables but did not include a correlation analysis.9
The differences are at least in part explained by the heterogeneity of
the groups investigated (see Figures 3–4). The strongest correlation be-
tween the EDSS and the RNFL was found for MS eyes which were not
affected by MSON.4,25 It is possible that the strong effect MSON has on
RNFL thickness (Figure 3) masks more subtle changes caused by ei-
ther asymptomatic axon damage or trans–synaptic axonal degeneration
in non–affected MS eyes.
Therefore, future treatment trials using OCT as a secondary outcome
measure for global disability will have to anticipate that predefined analy-
ses on patients without MSON are likely to be of stronger statistical power
than in patients with MSON and that alternative measures of disability
scoring that better reflect generalised neurologic functioning, including cog-
nition may need to be used which might better reflect diffuse axonal loss
in the CNS.
The Multiple Sclerosis Severity Score (MSSS) The MSSS was devel-
oped to overcome the problem of changes in the EDSS with different dis-
ease durations when comparing groups. There was no correlation of the
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RNFL with the MSSS in one study including patients with MSON.65
6 OCT and electrophysiology in MS
OCT allows to study of the structural properties of the retina thus com-
plimenting the many electrophysiological techniques aimed at functional
assessment. Research has been performed to find out possible associa-
tions between the two domains. Recalling the simplified sketch from Figure
6, one can formulate two key hypotheses to be tested: (1) is there a rela-
tionship between RNFL loss and VEP/PERG amplitude reduction (Figure
6 B)? (2) does VEP evidence for demyelination in the context of normal
anterior visual pathways predict later development of RNFL loss with tran-
synaptic retrograde degeneration (Figure 6 C)?
6.1 VEP
Following demyelination of the optic nerve the latency of visual evoked po-
tentials (VEP) are typically prolonged. This finding may persist for many
years and is regarded as a sensitive but not specific test. In a longitudinal
study Brusa et al. were first to note a small decline of the VEP ampli-
tude in the non–affected eye of MS patients with ON, suggesting that this
may be due to axonal loss.50 Advancing this concept, the same group
demonstrated that reduction of RNFL thickness was indeed related to re-
duced VEP (whole–field VEP and central–field VEP),26 a finding confirmed
by others.16,19,20,76 Klistorner et al. went on to show a high functional–
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topographic correlation between multifocal VEP and the RNFL (inferior VF,
R=0.84; superior VF, R=0.78; central VF, R=0.75; p<0.000 for all correla-
tions).77 Advances in multifocal VEP data analysis may render this tech-
nique more accessible.78 Some authors14,16,19,79 also found a correlation
between the RNFL and VEP latencies.
The association between reduction in RNFL and VEP amplitudes lends
further weight to the argument that demyelination related damage to the
ON may cause either direct axon damage or may occur in the postgenicu-
late visual pathway, leading to retrograde axonal degeneration of the non–
myelinated axons in the retina (Figure 6 B).
6.2 ERG
Using TD-OCT a correlation was found between the RNFL thickness and
pattern ERG P50 latency as well as with the P50-P95 amplitude.79 It was
suggested that this may be due to loss of ganglion cells following damage
to the optic nerve.79 Others did not find a convincing relationship between
the overall averaged RNFL and simple or multifocal ERG results,14 possi-
bly because multifocal ERG samples mainly the photoreceptor and bipolar
cell activation and not ganglion cells, therefore a correlation may not nec-
essarily be expected.
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7 OCT and imaging in MS
It is beyond the scope of this review to adequately address the results
of the body of literature on structural changes within the visual pathways
assessed by brain imaging techniques and the relationship to OCT data.
In brief, this relationship was investigated in a number of studies included
in our systematic review.11–13,24,25,80,81 These authors focused on optic
nerve imaging11,80,81 and full brain imaging techniques.11–13,24,25,46 The
published data suggest correlations of the RNFL with brain atrophy mea-
sures12,13,25 but a consensus has yet to emerge which atrophy measure
is the most relevant, with grey matter atrophy remaining a hot topic.11
Other measures potentially to be considered are the normalised brain vol-
ume,11,24 the T2 lesion volume,11,24,25 the magnetisation transfer ratio,11,81
the fractional anisotropy and diffusion tensor imaging.11,82 Less promis-
ing seem to be the T1 lesion volume11,13,25 and the mean parenchymal
diffusivity.11,46 For a more in–depth review see references.?, 3
8 Future developments
OCT and the macula in MS Changes of macular volume, as well as in-
ner and outer macular segments consistently show volume loss caused
by loss of retinal ganglion cells (RGC).12,15,19–23,26,32,37,83–85 All found the
macular volume to be reduced in patients with MS if compared to con-
trols. Loss of macular volume was correlated with loss of RNFL in 4 stud-
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ies.15,26,80,84 Of note retinal thickness in the macula is made up of many
RGCs (cones in the macula have a 1:1 correlation with RGCs where as in
the periphery many rods have a 1000:1 relationship with RGCs). There-
fore the macula provides a model to test hypotheses on primary neuronal
cell death followed by axonal loss. In a recent editorial,86 Waxman asked
three crucial questions: (1) what are the mechanisms involved in RGC
apoptosis? (2) could this be following axonal pathology or dysfunction?
(3) alternatively, could RGC apoptosis be an example of primary neuronal
injury independent from axonal damage?
Polarisation–sensitive OCT (PS-OCT) Specific tissue properties can
be further investigated by recording the polarisation state of back-scattered
light.87,88 Polarisation-sensitive OCT (PS-OCT) yields depth–resolved in-
formation on any light polarisation changing properties of the sample re-
lated to tissue birefringence.87,89–91 Importantly, birefringence of the RNFL
is related to the structure of dominant axonal filaments such as neuro-
filaments and microtubles.92 The birefringence of the RNFL induces a
quantifiable degree of phase retardation.89–91,93
The group of de Boer demonstrated that the birefringence of the RNFL
is not constant, but varies by a factor of 3 around the optic nerve head, with
higher values reported in the superior and inferior quadrants, and lower
values in the nasal and temporal quadrant.93 This distinguishes the RNFL
from other retinal structures which are either polarisation–preserving (e.g.
photoreceptor layer) or polarisation scrambling/depolarising (e.g. retinal
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pigmented epithelium, RPE).91 Because changes to the axonal cytoskele-
ton such as neurofilament compactness, phosphorylation and stoichiom-
etry can precede axonal loss,94,95 there may be a chance to detect early
stages of axonal pathology in MS using PS-OCT. Experimentally it has
already been shown that change in RNFL birefringence precedes RNFL
loss.96
Fluorescence labelling Fluorescence labelling of a protein (annexin 5)
which binds to a key component initiating apoptosis (phosphatidylserine)
allowed for real–time in vivo monitoring of RGC apoptosis.97 The detection
of apoptosing retinal cells (DARC) technique provides a promising surro-
gate outcome for neuroprotective treatment strategies in glaucoma, de-
mentia and potentially also MS.98,99 Analogous, labelling of mitochondria
may allow for in vivo testing of the “virtual hypoxia” hypothesis in MS.100
Retinal sector analysis This review did not include OCT data on sector
analysis of the retina. It can be hypothesised that retinal axons of certain
retinal sectors are more vulnerable then others in MS. Therefore, quanti-
tative analysis of these sectors may allow for sensitive detection of axonal
loss. However there is a large normal variation of the appearance of the
optic disc influencing the RNFL thickness which ought to be controlled
for.101,102
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RNFL thickness & reflectivity maps The accurate localisation of focal
and peripheral loss of retinal axons is challenging using individual circular
RNFL scans at the optic nerve head. One possible approach is the devel-
opment of RNFL thickness maps.90 Because the loss of retinal axons in
MS is more diffuse than the arcuate bundle loss seen in glaucoma it can
be speculated that an integrative approach combining PS-OCT data with
RNFL thickness maps may have the potential to predict the topography of
RNFL loss in MS.
Retinal layer segmentation algorithms With the introduction of SD/FD–
OCT retinal layer image quality potentially allows for segmentation and
quantification of individual layers. There is histological evidence that MS
not only affects the RNFL but also cellular layers.41 Therefore new seg-
mentation algorithms for quantitative analyses of individual retinal layers
may enable us to better investigate progression of neurodegeneration in
MS.
Doppler OCT and vascular changes in MS There is some evidence
that vascular co-morbidity is a poor prognostic sign in MS.103 Changes
of the retinal vasculature such as perivasculitis are recognised in MS.
Perivasculitis leads to extravascular hyaline deposits, hence the descrip-
tive name vascular sheathing. It is likely that these changes lead to a
more rigid retinal vasculature and thus a quicker pulse propagation from
the posterior (choriodal) to the anterior (retinal vasculature) circulation.17
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This could be investigate by combining SD-OCT with Doppler velocimetry
(SD-ODT). SD-ODT is non-invasive and allows for accurate topographic
localisation of retinal blood vessels.
OCM and action potentials The influence that action potential propa-
gation has on light properties has been recognised by Frank104 who cited
his work together with Kornakova105 in 1947. The field flourished over the
next 30 years (reviewed in106). Using optical coherence microscopy (OCM)
the structural assessment of an action potential became reality.107,108 At
present only in vitro monitoring of action potential propagation is possible.
Functional imaging of the human retina in vivo would be highly desirable
to investigate whether axonal dysfunction may precede RGC and/or RNFL
loss.
9 Conclusion
There is much excitement about OCT in MS research and it may be per-
mitted to cite one of the first neurologists who made extensive use of the
ophthalmoscope, Hughlings Jackson (1835-1911): “It is not too much to
say that, without an extensive knowledge of ophthalmology, a methodolog-
ical investigation of diseases of the nervous system is not merely difficult,
but impossible.”109
In conclusion, OCT is a relatively new and promising technique for po-
tential monitoring neuroprotective treatment trials in MS. First, there is a
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clear pathological correlate (axonal loss). Second, the analytical repro-
ducibility is excellent. Third, the sensitivity to change is twice as high as the
normal physiological changes during ageing and over a magnitude above
the averaged changes seen after ON. Fourth, it is of high clinical relevance,
correlating with clinical measures (loss of visual function) thus capturing a
fundamental feature associated with disability progression. Fifth, there is
data from brain imaging and electrophysiological studies which suggests
that the integration of OCT into MS research may allow for a more accurate
view of structure–function relationships in understanding the pathophysiol-
ogy of this enigmatic disease. Finally, it is predictive of a clinical outcome
(poor visual recovery). It is proposed to investigate the role OCT for future
MS research within a concentrated, resource saving approach using an
international workforce (OCTiMS).
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Figure 1: SD/FD–OCT image of a normal eye showing the different retinal
layers. The inlay shows an enlarged part of the optic disc (blue frame) and
macula (red frame).
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Figure 2: These hand sketched images illustrates probably for the first time
the development of axonal degeneration in the retina. At the time, this ob-
servation was only apparent thanks to two anatomical oddities coinciding.
Firstly the presence of myelinated axons within the retina (a developmen-
tal occurrence), seen here as a white bundle on the top and larger white
bundle on the bottom of the optic disc. Secondly, occurrence of a central
retinal artery occlusion in the same patient which caused retinal axon de-
generation over time. (A) A few dark gaps are visible between the inferior
bundle of myelinated axons (sketch taken 2 months after sudden loss of
vision in the right eye), indicating the beginning of loss of axons and their
myelination (B) axonal loss becomes more marked after 4 months and (C)
complete optic atrophy is the end result one year after a presumed embo-
lus of the central retinal artery in the 28 year old boy with a mitral valve
insufficiency. Bachmann already speculated in 1921 that the mechanism
leading to this fundus appearance may be due to ascending (Wallerian)
axonal degeneration. Note that the very occasion presence of myelinated
retinal axons as seen in this sketch will influence RNFL data acquired by
OCT, since intraretinal myelination results in a thicker, more highly reflec-
tive RNFL in those areas. MS patients in whom myelinated retinal axons
are observed can appear as normal or above normal outliers in treatment
trials using OCT as an outcome measure, especially if the myelinated reti-
nal axons are undamaged initially. Reprinted with permission from.40
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Figure 3: Meta–analysis of OCT studies in MS patients who did suffer from
MSON. The overall averaged RNFL (mean±SD) and number of eyes (not
subjects!) investigated is shown for patients and normal subjects. To the
right is the data expressed as micron difference in RNFL thickness of eyes
that had optic neuritis compared to normal eyes; length of horizontal bar is
the 95% confidence interval for each study.
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Figure 4: Meta-analysis of OCT studies in MS patients who did not suffer
from ON, by history. The overall averaged RNFL (mean±SD) and number
of eyes investigated is shown, similar to Figure 3 Note that the bar graph to
the right, which summarises the difference in RNFL in the asymptomatic
eyes compared to normal eyes, shows there is loss of RNFL even in eyes
supposedly not suffering from previous optic neuritis.
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Figure 5: Meta-analysis of OCT studies comparing MSON and non–
affected eyes in MS patients. The overall averaged RNFL (mean±SD)
and number of eyes investigated is shown. The difference between the
MSON and MS-non-ON eyes shown in this figure is less than the differ-
ence between MSON eyes and normal eyes Figure 3 (please note that the
scale of the x–axis differs between the two Figures).
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Figure 6: A model of the presumed relationship between RNFL thick-
ness and MS pathology. (A) A simplified sketch of the normal human
visual pathways. The retinal ganglion cells (RGC) send their unmyelinated
axons into the eye were they form the retinal nerve fibre layer (RNFL,
grey inlay), travel to the optic disc and leave the orbit. Once the axons
passed the sclera they become myelinated and form the optic nerve (ON).
After passing through the chiasma were the temporal fibres cross (not
shown) they are called the optic tract. The optic tract wraps around the
midbrain and enters the lateral geniculate nucleus (LGN) where all ax-
ons must synapse. After the LGN the axons fan out through the deep
white matter (optic radiations) to reach the occipital cortex. (B) MSON
(red) directly causes acute axonal loss in the ON (red dotted line) leading
to marked thinning of the RNFL (small grey box). (C) MS lesions within
the optic radiations (blue dotted line) do not immediately result in RNFL
thinning. This is thought to be a chronic consequence of trans–synaptic
axonal loss through the LGN. With time (black arrow) trans–synaptic ax-
onal degeneration causes a relative smaller degree of axonal loss in the
ON (red dashed–dotted line) with a quantifiable degree of RNFL loss (grey
box). (D) Progressive loss of RGC (yellow dot) is a likely result of chronic
changes in the anterior visual pathways themselves and causes a small
degree of RNFL loss (grey box).
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Figure 7: Longitudinal profile of OCT measurements in affected (ON) and
non–affected eyes from patients with MS. Image modified from reference7
with permission.
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